TMEM72 and central nervous system cancer: Compared with the primary glioma group, the expression of AC062021.1, FAM225B, LINC00662, LINC00665, and TMEM72-AS1 was significantly different in the recurrent glioma group of the training CGGA693 cohort (Figure 5C).